← Issue №18/ week of Nov 1, 2026/ the whole section, in full

Motility, in full.

All 6 Motility papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 6, in full

most clinically useful first
Motility meta analysis · Oct 26, 2026 · BMC Gastro · IF 2.5

Gut relief revisited: plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation - a systematic review and meta-analysis with GRADE assessment.

New evidencechronic constipationIBSmeta-analysissystematic review
Clinical takeawayConsider plecanatide, particularly the 3 mg dose, for adults with chronic idiopathic constipation (CIC) or irritable bowel syndrome with constipation (IBS-C), balancing efficacy and safety, while monitoring for diarrhea, the most frequent adverse event.
What it foundPlecanatide significantly increased complete spontaneous bowel movements (CSBMs) by 0.75-1.00 across doses compared to placebo, with the greatest improvement at 9 mg, and improved spontaneous bowel movements (SBMs) by 0.97-1.58 at 1-6 mg.
ContextConfirms plecanatide's efficacy and safety in adults with CIC and IBS-C, refining dose selection with evidence supporting 3 mg as optimal, though diarrhea remains a dose-related concern.
Measured against the standard of care· AGA-ACG 2023 (Chang L et al., Am J Gastroenterol 2023;118:936-954, doi 10.14309/ajg.0000000000002227) / AGA Clinical Practice Update 2026 (Staller K et al., Clin Gastroenterol Hepatol 2026;24(2):296-305, doi 10.1016/j.cgh.2025.09.031, PMID 41504675) / ASCRS-ICS-IUGA-AUGS-APTA Pelvic Floor Consortium consensus 2026 (Traugott AL et al., Dis Colon Rectum 2026;69(3):346-359, doi 10.1097/DCR.0000000000003993)

First-line drug treatment for adults with chronic idiopathic constipation has not changed. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

First-line drug treatment for adults with chronic idiopathic constipation has not changed. It still follows the AGA-ACG 2023 GRADE guideline. STRONG recommendation (moderate certainty) for polyethylene glycol. STRONG recommendation (moderate certainty) for bisacodyl or sodium picosulfate, limited to short-term or rescue use. CONDITIONAL suggestion for fiber (low certainty), magnesium oxide (very low) and senna (low). For patients who do not respond to, fail, or cannot tolerate over-the-counter agents: STRONG recommendation (moderate certainty) for linaclotide, plecanatide and prucalopride, and CONDITIONAL suggestion for lubiprostone (low) and lactulose (very low). The guideline gives no doses, no required order and no fixed trial length; it uses shared decision making and leaves anorectal evacuation disorders to the ACG 2021 benign anorectal guideline. Added on top of this is the AGA 2026 Clinical Practice Update on refractory constipation (Staller, Neshatian, Lembo, Bharucha; expert-opinion Best Practice Advice, 14 key clinical issues, no formal evidence grading). Before calling constipation refractory, clinicians should systematically (1) exclude correctable secondary causes: medications, neurologic disorders, and defecatory disorders; (2) confirm slow colonic transit objectively, ideally both off therapy and on maximal therapy; and (3) make sure the patient has had adequate trials of over-the-counter and FDA-approved drugs and nonpharmacologic therapy, including combinations. Most patients should have anorectal testing and, when indicated, pelvic floor biofeedback before being labeled refractory. Colectomy can be considered only after all of these fail. Before surgery: confirm slow transit, exclude a concurrent defecatory disorder, evaluate for severe symptomatic delayed gastric emptying or small-bowel dysmotility, and do a psychological evaluation. Relative contraindications are clinically significant upper-gut dysmotility, severe untreated psychiatric disease, and bloating or abdominal pain as the main complaint. A temporary diverting loop ileostomy may predict response in uncertain cases. Colectomy with ileorectal anastomosis should be offered only to patients without an ongoing defecatory disorder. For obstructed defecation and posterior compartment or rectal prolapse, a 2026 consensus of the ASCRS Pelvic Floor Consortium with ICS, IUGA, AUGS and APTA (15 statements, >70% consensus, expert-consensus evidence) advises prompt referral to pelvic floor physical therapy for patients without contraindications. It also advises therapy individualized to the diagnostic evaluation and the patient's goals, deliberate timing of therapy relative to surgery, and trauma-informed care.

AGA-ACG 2023 (Chang L et al., Am J Gastroenterol 2023;118:936-954, doi 10.14309/ajg.0000000000002227) / AGA Clinical Practice Update 2026 (Staller K et al., Clin Gastroenterol Hepatol 2026;24(2):296-305, doi 10.1016/j.cgh.2025.09.031, PMID 41504675) / ASCRS-ICS-IUGA-AUGS-APTA Pelvic Floor Consortium consensus 2026 (Traugott AL et al., Dis Colon Rectum 2026;69(3):346-359, doi 10.1097/DCR.0000000000003993) · reviewed 2026-10-25 ↗
Aboelkhier MM … Alsayed AR · BMC Gastroenterology · IF 2.5 · PubMed ↗Permalink
Motility retrospective · n=502 · Oct 30, 2026 · J Neurogastro Motil · IF 3.4

Development of a Simplified Clinical Score for Defecation Disorder.

Diagnosticchronic constipationartificial intelligenceepidemiology
Clinical takeawayConsider using the STRAIN score to identify defecation disorder in patients with refractory constipation when anorectal manometry (ARM) is unavailable.
What it foundThe STRAIN score (11-point scale) for defecation disorder showed AUROC 0.91 in derivation and 0.88 in validation cohorts, with ≥6 cutoff yielding 87.2% sensitivity and 83.2% specificity. The score assigns points as follows: straining (3 points), ≥3 bowel movements/week (2 points), rectal blockage sensation (2 points), assisted defecation (2 points), incomplete evacuation (1 point), and new-onset symptoms ≤2 years (1 point).
ContextThis retrospective study challenges reliance on ARM for DD diagnosis, offering a validated clinical alternative for settings lacking access to physiological testing.
Measured against the standard of care· AGA-ACG 2023 (Chang L et al., Am J Gastroenterol 2023;118:936-954, doi 10.14309/ajg.0000000000002227) / AGA Clinical Practice Update 2026 (Staller K et al., Clin Gastroenterol Hepatol 2026;24(2):296-305, doi 10.1016/j.cgh.2025.09.031, PMID 41504675) / ASCRS-ICS-IUGA-AUGS-APTA Pelvic Floor Consortium consensus 2026 (Traugott AL et al., Dis Colon Rectum 2026;69(3):346-359, doi 10.1097/DCR.0000000000003993)

Decision at stakediagnosing defecatory disorders in patients with refractory constipation

… Before calling constipation refractory, clinicians should systematically (1) exclude correctable secondary causes: medications, neurologic disorders, and defecatory disorders; (2) confirm slow colonic transit objectively, ideally both off therapy and on maximal therapy; and (3) make sure the patient has had adequate trials of over-the-counter and FDA-approved drugs and nonpharmacologic therapy, including combinations. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

First-line drug treatment for adults with chronic idiopathic constipation has not changed. It still follows the AGA-ACG 2023 GRADE guideline. STRONG recommendation (moderate certainty) for polyethylene glycol. STRONG recommendation (moderate certainty) for bisacodyl or sodium picosulfate, limited to short-term or rescue use. CONDITIONAL suggestion for fiber (low certainty), magnesium oxide (very low) and senna (low). For patients who do not respond to, fail, or cannot tolerate over-the-counter agents: STRONG recommendation (moderate certainty) for linaclotide, plecanatide and prucalopride, and CONDITIONAL suggestion for lubiprostone (low) and lactulose (very low). The guideline gives no doses, no required order and no fixed trial length; it uses shared decision making and leaves anorectal evacuation disorders to the ACG 2021 benign anorectal guideline. Added on top of this is the AGA 2026 Clinical Practice Update on refractory constipation (Staller, Neshatian, Lembo, Bharucha; expert-opinion Best Practice Advice, 14 key clinical issues, no formal evidence grading). Before calling constipation refractory, clinicians should systematically (1) exclude correctable secondary causes: medications, neurologic disorders, and defecatory disorders; (2) confirm slow colonic transit objectively, ideally both off therapy and on maximal therapy; and (3) make sure the patient has had adequate trials of over-the-counter and FDA-approved drugs and nonpharmacologic therapy, including combinations. Most patients should have anorectal testing and, when indicated, pelvic floor biofeedback before being labeled refractory. Colectomy can be considered only after all of these fail. Before surgery: confirm slow transit, exclude a concurrent defecatory disorder, evaluate for severe symptomatic delayed gastric emptying or small-bowel dysmotility, and do a psychological evaluation. Relative contraindications are clinically significant upper-gut dysmotility, severe untreated psychiatric disease, and bloating or abdominal pain as the main complaint. A temporary diverting loop ileostomy may predict response in uncertain cases. Colectomy with ileorectal anastomosis should be offered only to patients without an ongoing defecatory disorder. For obstructed defecation and posterior compartment or rectal prolapse, a 2026 consensus of the ASCRS Pelvic Floor Consortium with ICS, IUGA, AUGS and APTA (15 statements, >70% consensus, expert-consensus evidence) advises prompt referral to pelvic floor physical therapy for patients without contraindications. It also advises therapy individualized to the diagnostic evaluation and the patient's goals, deliberate timing of therapy relative to surgery, and trauma-informed care.

AGA-ACG 2023 (Chang L et al., Am J Gastroenterol 2023;118:936-954, doi 10.14309/ajg.0000000000002227) / AGA Clinical Practice Update 2026 (Staller K et al., Clin Gastroenterol Hepatol 2026;24(2):296-305, doi 10.1016/j.cgh.2025.09.031, PMID 41504675) / ASCRS-ICS-IUGA-AUGS-APTA Pelvic Floor Consortium consensus 2026 (Traugott AL et al., Dis Colon Rectum 2026;69(3):346-359, doi 10.1097/DCR.0000000000003993) · reviewed 2026-10-25 ↗
Geeratragool T … Charernboon T · Journal of Neurogastroenterology and Motility · IF 3.4 · PubMed ↗Permalink
Motility retrospective · n=3,508 · Oct 27, 2026 · Aliment Pharm Ther · IF 6.7

Colonic Mast Cell Density and Diarrhoea: Evidence Against a Threshold Effect in Biopsies From 3508 Patients.

New evidencebasic scienceepidemiologybiomarker
Clinical takeawayAvoid routine quantification of mast cells in colonic biopsies for patients with chronic diarrhoea or nonspecific abdominal symptoms, as it does not correlate with symptom presence.
What it foundDiarrhoea prevalence was similar across mast cell (MC) count groups: 58.3% (<20 MC/hpf), 54.1% (20-39 MC/hpf), 54.7% (40-59 MC/hpf), 50.0% (60-98 MC/hpf), and 33.3% (≥99 MC/hpf), compared to standard diagnostic approaches.
ContextChallenges the practice of incorporating mast cell quantification into histologic evaluation for common GI symptoms, which has been controversial due to unclear clinical relevance. This recommendation applies to patients with chronic diarrhoea or nonspecific abdominal symptoms.
Emergingsuggested applicable standard· British Society of Gastroenterology, Arasaradnam RP, et al. "Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition." Gut, 2018;67(8):1380-1399.

In an adult with chronic diarrhoea (loose or watery stools persisting >4 weeks) and a macroscopically normal colonoscopy, take biopsies from BOTH the right (proximal) and left (distal) colon to exclude microscopic colitis; because microscopic colitis has a patchy distribution, one-sided (e.g. rectosigmoid-only) biopsies are no longer recommended. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

In an adult with chronic diarrhoea (loose or watery stools persisting >4 weeks) and a macroscopically normal colonoscopy, take biopsies from BOTH the right (proximal) and left (distal) colon to exclude microscopic colitis; because microscopic colitis has a patchy distribution, one-sided (e.g. rectosigmoid-only) biopsies are no longer recommended. Investigation is tiered rather than a fixed panel. First-line screening (primary care): full blood count, ferritin, CRP, coeliac serology (anti-tTG), thyroid function, and faecal calprotectin, with stool culture, the screening bloods/coeliac/faecal-inflammation tests carry a strong recommendation. If first-line tests are normal and symptoms persist, secondary-care testing is directed by the clinical picture: SeHCAT or fasting serum 7α-hydroxy-4-cholesten-3-one (C4) for suspected bile acid diarrhoea, faecal elastase for pancreatic exocrine insufficiency, lactose/hydrogen breath testing for carbohydrate maldigestion, and, for suspected SIBO, an empirical trial of antibiotics, which the guideline recommends as the practical approach (strong recommendation) because there is insufficient evidence to recommend routine hydrogen or methane breath testing and it does not endorse jejunal aspirate as the routine preferred test. A functional/IBS diagnosis is appropriate when there are typical functional symptoms, a normal examination, and normal screening investigations; younger patients (<40) with atypical or persistent symptoms warrant specialist review even if faecal calprotectin is normal.

British Society of Gastroenterology, Arasaradnam RP, et al. "Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition." Gut, 2018;67(8):1380-1399. · reviewed 2026-07-23 ↗
Langreiter M … Schreiner P · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink
Motility prospective cohort · n=100 · Oct 30, 2026 · J Neurogastro Motil · IF 3.4

Delayed Gastric Emptying Is Associated With Progression to End-Stage Renal Disease in Diabetic Patients With Chronic Upper Gastrointestinal Symptoms.

New evidencegastroparesis
Clinical takeawayA retrospective association in 100 patients (5-year ESRD 35% vs 9%); it does not test whether gastric emptying results should change kidney monitoring.
What it foundDelayed gastric emptying tripled ESRD risk in diabetic patients with chronic UGI symptoms (HR 3.12, 95% CI 1.34-7.97), with 5-year ESRD incidence of 35% in delayed GE vs 9% in normal GE.
ContextIdentifies delayed GE as a novel risk factor for ESRD progression in diabetic patients with chronic UGI symptoms, refining risk stratification beyond traditional markers.
Emergingsuggested applicable standard· American Gastroenterological Association (AGA), "AGA Clinical Practice Guideline on Management of Gastroparesis," 2025

Scope: AGA 2025 addresses adults with idiopathic or diabetic gastroparesis; it does not issue diabetes-specific graded recommendations, and every one of its 12 recommendations is CONDITIONAL ("we suggest"), with explicit shared-decision-making carve-outs. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Scope: AGA 2025 addresses adults with idiopathic or diabetic gastroparesis; it does not issue diabetes-specific graded recommendations, and every one of its 12 recommendations is CONDITIONAL ("we suggest"), with explicit shared-decision-making carve-outs. Diagnosis: the AGA suggests AGAINST a 2-hour (or shorter) gastric emptying study and in favor of a 4-hour study (conditional, low certainty); the 4-hour value must be measured directly, not mathematically extrapolated from earlier time points, and the study should be done off confounders (opioids, GLP-1 receptor agonists, prokinetics) and without hyperglycemia. Pharmacotherapy, FOR: the AGA suggests using metoclopramide over no metoclopramide (conditional, VERY LOW certainty), typically oral or intranasal starting at 5 mg before meals titrated up to 10 mg before meals, noting the FDA black-box tardive dyskinesia warning and 12-week prescribing limit while observing that absolute tardive dyskinesia risk is low (~1 in 17,800 to 1 in 35,000 prescriptions); and suggests using erythromycin over no erythromycin (conditional, VERY LOW certainty), low-dose 100-150 mg orally 30 minutes before meals, with drug holidays (e.g. 3 weeks on, 1 week off) to counter tachyphylaxis. Efficacy of any pharmacologic agent should be reassessed at 4 to 8 weeks to decide on continuation. Pharmacotherapy, AGAINST (all conditional): domperidone (very low certainty; patients valuing improvement in nausea, vomiting and early satiety over adverse events may reasonably elect it where available, and it may suit those with neurologic side effects on metoclopramide or with Parkinson's disease; requires an FDA IND, with baseline potassium, magnesium and QTc monitoring); prucalopride (very low certainty; patients with idiopathic gastroparesis, or with coexisting chronic idiopathic constipation, may reasonably elect it); aprepitant (low certainty; may help when 5-HT3 antagonists such as ondansetron are not helpful); nortriptyline (low certainty; may reasonably be elected by patients with co-occurring irritable bowel syndrome or significant abdominal pain, started low at 10-25 mg and titrated slowly); buspirone (very low certainty; may help predominant early satiety and bloating); and cannabidiol except in the context of a clinical trial (low certainty). Procedures, all AGAINST, all conditional: G-POEM, except for selected patients with medically refractory disease (low certainty), candidates should have gastroparesis on an appropriately performed 4-hour study, generally at least moderate delay (≥20% retention at 4 hours with the EggBeaters meal), at least 6 months of moderate cardinal symptoms, and a prior trial of a prokinetic such as metoclopramide plus at least one antiemetic; intrapyloric botulinum toxin injection in medically refractory gastroparesis (very low certainty), noting retreatment as often as every 3 months and the risk that repeat injection causes pyloric scarring complicating later G-POEM; and gastric electrical stimulation in medically refractory gastroparesis (very low certainty), noting a roughly 7% serious adverse event rate, that patients should be told GES targets nausea and vomiting rather than abdominal pain, and that patients valuing nausea/vomiting improvement over that risk may reasonably select placement. Surgical pyloric intervention: the AGA recommends surgical pyloromyotomy or pyloroplasty ONLY in the context of clinical trials, designated a knowledge gap, with no recommendation for or against. Ungraded general implementation considerations (explicitly not GRADE recommendations): optimize glycemic control in gastroparesis in the setting of diabetes; review and eliminate medications that delay gastric emptying (opioids, GLP-1 receptor agonists); use small-particle, low-fat, low-residue diets before or alongside pharmacotherapy; and use antiemetics as needed (5-HT3 antagonists such as ondansetron, H1 antagonists such as promethazine, D2 antagonists such as prochlorperazine).

American Gastroenterological Association (AGA), "AGA Clinical Practice Guideline on Management of Gastroparesis," 2025 · reviewed 2026-07-19 ↗
Chung JO … Chung DJ · Journal of Neurogastroenterology and Motility · IF 3.4 · PubMed ↗Permalink
Motility prospective cohort · n=480 · Oct 30, 2026 · J Neurogastro Motil · IF 3.4

Psychological Predictors of Symptom Severity in Disorders of Gut-Brain Interaction: A Machine Learning Approach.

New evidenceartificial intelligencebiomarkerbasic science
Clinical takeawayConsider routine somatic anxiety screening in gastroenterology for DGBI patients to identify candidates for brain-gut behavioral therapies.
What it foundAnxiety symptoms (Cohen's d = 0.55-0.92) were the primary psychological determinant of DGBI severity in a cohort of 480 patients, with childhood trauma associations likely mediated through anxiety and depression pathways. The incremental value of multidimensional psychological profiling beyond anxiety assessment alone was limited (AUC = 0.750 vs. 0.753).
ContextConfirms the central role of anxiety in DGBI severity and suggests limited incremental value of multidimensional psychological profiling beyond anxiety assessment alone.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Yoon SH … Lee SY · Journal of Neurogastroenterology and Motility · IF 3.4 · PubMed ↗Permalink
Motility review · Oct 30, 2026 · J Neurogastro Motil · IF 3.4

Acid-Lowering Agents in Functional Dyspepsia: Assessing the Role and Effectiveness of Proton Pump Inhibitors and Beyond.

Guideline / reviewfunctional dyspepsiameta-analysissystematic review
Clinical takeawayMeta-analyses show PPIs beat placebo for global functional dyspepsia symptoms, most consistently for epigastric pain and burning; the review flags possible long-term effects and calls P-CABs promising but unproven against PPIs.
What it foundPPIs are superior to placebo for global symptom relief in FD, with the most consistent benefits observed for epigastric pain and burning.
ContextConfirms PPIs as the standard first-line therapy for FD, while highlighting newly discovered non-acid-related mechanisms and introducing P-CABs as a potential future option. Applies to FD patients with epigastric pain or burning.
Reinforcessuggested applicable standard· American College of Gastroenterology, 'ACG and CAG Clinical Guideline: Management of Dyspepsia', 2017

Decision at stakethe use of PPIs for functional dyspepsia

After excluding organic causes and confirming H. pylori test-of-cure, manage functional dyspepsia by eradicating H. pylori if positive and giving a PPI (4-8 weeks, dosed 30-60 min before meals); for persistent symptoms consider neuromodulators (e.g., low-dose TCAs like amitriptyline 10-50 mg QHS) for refractory cases, particularly in EPS, or prokinetics cautiously in selected PDS cases. Initial evaluation follows ACG/CAG 2017: test-and-treat H. pylori in patients under 60 without alarm features, and EGD for age ≥60, alarm features, or high gastric-cancer-risk groups. Add psychological therapies (CBT, gut-directed hypnotherapy) and lifestyle measures.

American College of Gastroenterology, 'ACG and CAG Clinical Guideline: Management of Dyspepsia', 2017 · reviewed 2026-07-21 ↗
Ma R, Xiao Y · Journal of Neurogastroenterology and Motility · IF 3.4 · PubMed ↗Permalink
← Back to issue №18 Every section of this issue is one click away, at the top of this page. Follow Motility by RSS